ArticleRheumatology (Oxford, England)2026
Treatment of systemic sclerosis-associated pulmonary hypertension with and without interstitial lung disease and its impact on survival: a large cohort study of the German network for systemic sclerosis.
Article in Rheumatology (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
objectivesThis study aimed to analyse survival in SS-associated pulmonary hypertension (SSc-PH) patients with or without interstitial lung disease (ILD) stratified by PH monotherapy and PH combination therapy, respectively.
methodsAmong the 6003 patients registered with the German Network for Systemic Sclerosis (DNSS) registry, SSc patients with incident PH diagnosed after registry entry were included. Kaplan-Meier analysis was performed to estimate the overall survival, and the log-rank test was used to assess differences between groups stratified by the presence of ILD or PH treatment.
resultsOf, the 384 patients who fulfilled the inclusion criteria, 271 had concomitant ILD (70.6%). The mean follow-up period was 8.69 ± 4.94 years. Forced vital capacity (FVC) and diffusing capacity of the lungs for carbon monoxide (DLCO) numerically decreased in PH patients with and without ILD and were significantly lower in patients with ILD (mean value of minimal FVC during follow-up: 70.79 ± 24.36%). There was no significant difference in the distribution of PH therapy categories (mono, dual, or triple therapy) between PH patients with and without ILD involvement (P = 0.865). No survival difference was observed between the monotherapy and combination therapy groups (P = 0.197). Subgroup analysis indicated that varying the treatment strategies did not significantly impact the survival outcomes of PH patients, whether or not ILD was present.
conclusionSSc patients with ILD and incident PH are often treated with PH combination therapy in Germany. This treatment strategy seems feasible and does not worsen survival in PH patients, provided that ILD is not severe.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.